| Sign In to gain access to subscriptions and/or personal tools. |
Workshop report on some new ideas about the treatment of systemic lupus erythematosusLa Jolla Pharmaceuticals, San Diego, California, USA
Infection and Immunity Research Group, Kings College London, London, UK
Department of Nephrology, Nijmegen University, Nijmegen, Germany
Centre for Rheumatology, University College London, London, UK; Centre for Rheumatology, 4th floor, Arthur Stanley House, 40–50 Tottenham Street, London W1T 4NJ, UK. Our increased understandingof the pathogenesisof systemic lupus erythematosus is leading to new ideas about its therapy. In this session of the workshop the use of LJP 394 a B cell toleragen and the use of an anti-CD20 monoclonal antibody were discussed in some detail. Their rationale and early clinical results were reviewed; both have shown encouraging clinical and serological benefi t. Defi nitive double-blind clinical trials are still, however, awaited. In addition, the intriguing notion of using a nasal instillation of a histone peptide was described and early work in an experimental model presented.
Key Words: SLE • anti DNA antibody • histone peptide
Lupus, Vol. 11, No. 12,
793-796 (2002) This article has been cited by other articles:
|
|||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
